Holen Sie sich die Stockscreener-App
1.27
0.00%
0.00
Handel nachbörslich:
1.20
-0.07
-5.51%
Pasithea Therapeutics Corp Aktie (KTTA) Neueste Nachrichten
Pasithea Therapeutics to Present at the 2025 CAGLA NeauxCancer Conference - The Manila Times
Pasithea Therapeutics to Present at 2025 CAGLA NeauxCancer Conference on Next-Generation MEK Inhibitor PAS-004 - Nasdaq
New Clinical Data: Pasithea's Novel Cancer Drug Shows Promise in Phase 1 Trial - Stock Titan
KTTA stock touches 52-week low at $1.12 amid market challenges - Investing.com India
KTTA stock touches 52-week low at $1.12 amid market challenges By Investing.com - Investing.com South Africa
KTTA stock touches 52-week low at $1.24 amid market challenges - Investing.com Australia
KTTA stock touches 52-week low at $1.24 amid market challenges By Investing.com - Investing.com South Africa
Pasithea's PAS-004 advances in cancer trial with no toxicities - MSN
KTTA stock touches 52-week low at $1.32 amid market challenges - Investing.com Nigeria
Pasithea Therapeutics Corp. (NASDAQ:KTTA) Short Interest Update - Defense World
Pasithea Therapeutics Corp (KTTA) Stock: A Study of the Market Performance - The News Heater
An analyst sees good growth prospects for Pasithea Therapeutics Corp (KTTA) - SETE News
Daily Progress: Pasithea Therapeutics Corp (KTTA) Drop -21.90, Closing at 2.14 - The Dwinnex
Big Mid-Week Move From This Small Biotech - The Globe and Mail
KTTA stock touches 52-week low at $2.19 amid market challenges - MSN
Pasithea Therapeutics Corp (KTTA) Stock: Navigating Drops and Gains - The InvestChronicle
Understanding KTTA’s financial ratios: A beginner’s guide - US Post News
Pasithea (KTTA) Stock Spikes On Its Latest Clinical Trial Milestone - Stocks Telegraph
Pasithea Therapeutics Shares Rise After Positive Safety Review for Cancer Treatment - MarketWatch
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer - Marketscreener.com
Top Premarket Gainers -February 05, 2025 at 07:47 am EST - Marketscreener.com
Pasithea announces Safety Review Committee recommendation - TipRanks
Pasithea's PAS-004 advances in cancer trial with no toxicities By Investing.com - Investing.com UK
Pasithea Therapeutics Announces Positive Safety Review - GlobeNewswire
Clinical Trial Breakthrough: Cancer Drug Shows Unprecedented Safety Profile in Phase 1 - StockTitan
US Stocks Mixed; Walt Disney Posts Upbeat Earnings - Benzinga
Pasithea Therapeutics Corp. (NASDAQ:KTTA) Short Interest Up 37.2% in December - Defense World
Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4 - GlobeNewswire
Pasithea Therapeutics Corp. Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4 - Marketscreener.com
KTTA stock touches 52-week low at $2.33 amid market challenges - Investing.com Australia
KTTA stock touches 52-week low at $2.33 amid market challenges By Investing.com - Investing.com South Africa
Analyzing Galecto (NASDAQ:GLTO) and Pasithea Therapeutics (NASDAQ:KTTA) - Defense World
Analyzing Pasithea Therapeutics (NASDAQ:KTTA) and MusclePharm (OTCMKTS:MSLP) - Defense World
KTTA stock touches 52-week low at $2.72 amid market challenges - Investing.com Nigeria
KTTA stock touches 52-week low at $2.72 amid market challenges By Investing.com - Investing.com South Africa
KTTA stock touches 52-week low at $2.87 amid market challenges - Investing.com Nigeria
Pasithea Therapeutics Announces Positive Safety Review Committee Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer - Marketscreener.com
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):